Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up

Chao Zhang, Siyang Liu, Benyuan Jiang, Zhiyong Chen, Lixu Yan, Zhenbin Qiu, Juntao Lin, Xuening Yang, Yilong Wu, Hao Sun, Wenzhao Zhong

Open source

DOI: 10.1097/cm9.0000000000003798
Published: 2025-10-24
Container: Chinese Medical Journal
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/cm9.0000000000003798,
  title = {Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up},
  author = {Chao Zhang and Siyang Liu and Benyuan Jiang and Zhiyong Chen and Lixu Yan and Zhenbin Qiu and Juntao Lin and Xuening Yang and Yilong Wu and Hao Sun and Wenzhao Zhong},
  year = {2025},
  journal = {Chinese Medical Journal},
  doi = {10.1097/cm9.0000000000003798},
  url = {https://doi.org/10.1097/cm9.0000000000003798}
}

RIS

TY  - JOUR
TI  - Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up
AU  - Chao Zhang
AU  - Siyang Liu
AU  - Benyuan Jiang
AU  - Zhiyong Chen
AU  - Lixu Yan
AU  - Zhenbin Qiu
AU  - Juntao Lin
AU  - Xuening Yang
AU  - Yilong Wu
AU  - Hao Sun
AU  - Wenzhao Zhong
PY  - 2025
JO  - Chinese Medical Journal
DO  - 10.1097/cm9.0000000000003798
UR  - https://doi.org/10.1097/cm9.0000000000003798
ER  -

APA

Zhang, C., Liu, S., Jiang, B., Chen, Z., Yan, L., Qiu, Z., Lin, J., Yang, X., Wu, Y., Sun, H., & Zhong, W. (2025). Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up. Chinese Medical Journal. https://doi.org/10.1097/cm9.0000000000003798

Source records

crossref · retrieved 2026-09-26T15:22:25.184Z